Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced on Friday that it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for Opdivo (nivolumab) in combination with chemotherapy for neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC) at high risk of recurrence in patients with tumour cell PD-L1 expression ≥1%.
This recommendation was based on Phase 3 CheckMate -816 trial results, showing improved event-free survival and pathologic complete response compared to chemotherapy alone when given before surgery.
If approved, Opdivo with chemotherapy would be the first neoadjuvant immunotherapy-based option for NSCLC patients in the European Union.
The CHMP recommendation will now be reviewed by the European Commission.
Opdivo has already been approved for neoadjuvant treatment of resectable NSCLC in multiple countries, including the United States, Japan and China. Opdivo-based treatments have demonstrated efficacy in neoadjuvant or adjuvant treatment of lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration